Inna M. Chen
YOU?
Author Swipe
View article: 41 Pharmacodynamic changes in collagen-derived immune biomarkers predict treatment response in patients with metastatic biliary tract cancer treated with immunotherapy and radiotherapy
41 Pharmacodynamic changes in collagen-derived immune biomarkers predict treatment response in patients with metastatic biliary tract cancer treated with immunotherapy and radiotherapy Open
View article: 543 VIDAR-1: a phase 1/2a master protocol for open-label, multi-centre, single-arm, first-in-human clinical studies of autologous TCR-T therapy targeting mutant KRAS in metastatic or locally advanced PDAC
543 VIDAR-1: a phase 1/2a master protocol for open-label, multi-centre, single-arm, first-in-human clinical studies of autologous TCR-T therapy targeting mutant KRAS in metastatic or locally advanced PDAC Open
View article: The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST Open
Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates…
View article: Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis
Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis Open
Although the incidence of ICI-related NAEs is low such side effects may lead to severe morbidity and mortality. In patients with Triple M syndrome intensive respiratory function monitoring and support are essential parameters to improve th…
View article: Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma
Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma Open
Introduction Metastatic pancreatic ductal adenocarcinoma (PDAC) is highly lethal. Promoter hypermethylation of SFRP1 (phSFRP1) in cell-free DNA is an established prognostic biomarker in PDAC. We used digital droplet PCR (ddPCR) to examine …
View article: Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer
Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer Open
Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the Ch…
View article: Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma
Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma Open
The extracellular matrix (ECM) protein Beta-Ig H3 (βigH3, also known as transforming growth factor β induced protein (TGFBI)) is related to poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Proteolytic cleavage of βi…
View article: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia Open
PURPOSE This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557 ) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti–interleukin-6 (IL-6) receptor antibody tocilizumab (Toc) for advanced p…
View article: A study of a supportive application with integrated patient-reported outcomes in patients with advanced pancreatic or lung cancer (BetterEveryDay)
A study of a supportive application with integrated patient-reported outcomes in patients with advanced pancreatic or lung cancer (BetterEveryDay) Open
ID NCT04611867 (BetterEveryDay); Registration date November 2, 2020.
View article: Paired Comparison of Whole Genome Sequencing and Comprehensive Targeted Sequencing of Pancreatic Cancer Tissue
Paired Comparison of Whole Genome Sequencing and Comprehensive Targeted Sequencing of Pancreatic Cancer Tissue Open
A comparable number of variants were reported by WGS and OCA-Plus, and all genetic variants relevant for targeted therapy were identified by both technologies. Thus, WGS does not provide substantial additional information in this patient g…
View article: Elevated Levels of Cleaved Soluble Forms of Urokinase-Type Plasminogen Activator Receptor are Associated with Poor Survival in Advanced Pancreatic Cancer
Elevated Levels of Cleaved Soluble Forms of Urokinase-Type Plasminogen Activator Receptor are Associated with Poor Survival in Advanced Pancreatic Cancer Open
View article: The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling Open
Although interleukin (IL)-6 is considered immunosuppressive and tumor-promoting, emerging evidence suggests that it may support antitumor immunity. While combining immune checkpoint inhibitors (ICIs) and radiotherapy in patients with pancr…
View article: 1357 βigH3 derived from stromal cells mediates pathological TGF-β activity in pancreatic fibroblasts and is a potential target for treating cancer patients with high fibrotic activity
1357 βigH3 derived from stromal cells mediates pathological TGF-β activity in pancreatic fibroblasts and is a potential target for treating cancer patients with high fibrotic activity Open
View article: 51 Fibroblast activation protein (FAP) generates a specific type III collagen fragment detectable in serum that associates with survival outcomes in patients with pancreatic ductal adenocarcinoma
51 Fibroblast activation protein (FAP) generates a specific type III collagen fragment detectable in serum that associates with survival outcomes in patients with pancreatic ductal adenocarcinoma Open
View article: 194 Discovering pan-cancer immune signatures by investigating changes in peripheral immune cell composition using flow cytometry and clustering to elucidate mechanisms underlying response to treatment
194 Discovering pan-cancer immune signatures by investigating changes in peripheral immune cell composition using flow cytometry and clustering to elucidate mechanisms underlying response to treatment Open
View article: Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT)
Transition of Online Adaptive Stereotactic Radiotherapy for Pancreatic Cancer From Magnetic Resonance-Guided Linear Accelerator (MR-Linac) to State-of-the-Art Cone-Beam Computed Tomography (CBCT) Open
Pancreatic cancer is one of the most challenging tumor sites to treat safely and effectively with radiotherapy due to the anatomical location and aggressiveness of the disease. One modality that has shown promising results, which our insti…
View article: Immune Checkpoint Inhibitor–Induced Cardiotoxicity
Immune Checkpoint Inhibitor–Induced Cardiotoxicity Open
Importance Immune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur. Objective To determine the incidence of CVAEs and an…
View article: Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Trial protocol
View article: Supplementary Tables S1-S15 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Tables S1-S15 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Table S1. List of antibodies used for immunohistochemistry analysis Supplementary Table S2. Detailed description on SBRT and BOR for all the cases Supplementary Table S3. SBRT targets according to treatment group Supplementar…
View article: Supplementary Data S2 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Data S2 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Consort Checklist
View article: Data from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Data from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Purpose:The purpose of this study was to evaluate the clinical benefits of nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients with pretreated metastatic biliary tract cancer (mBTC).Patients an…
View article: Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Data S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Trial protocol
View article: Supplementary Figures S1-S22 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Figures S1-S22 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Figure S1. CheckPAC study design Supplementary Figure S2. Best percentage change in target lesions from baseline in evaluable patients Supplementary Figure S3. Kaplan–Meier plot of PFS and OS in SBRT/nivolumab/ipilimumab-grou…
View article: Data from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Data from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Purpose:The purpose of this study was to evaluate the clinical benefits of nivolumab with/without ipilimumab combined with stereotactic body radiotherapy (SBRT) in patients with pretreated metastatic biliary tract cancer (mBTC).Patients an…
View article: Supplementary Data S2 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Data S2 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Consort Checklist
View article: Supplementary Figures S1-S22 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Figures S1-S22 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Figure S1. CheckPAC study design Supplementary Figure S2. Best percentage change in target lesions from baseline in evaluable patients Supplementary Figure S3. Kaplan–Meier plot of PFS and OS in SBRT/nivolumab/ipilimumab-grou…
View article: Supplementary Results S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Results S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Results
View article: Supplementary Results S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Results S1 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Results
View article: Supplementary Tables S1-S15 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study
Supplementary Tables S1-S15 from Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study Open
Supplementary Table S1. List of antibodies used for immunohistochemistry analysis Supplementary Table S2. Detailed description on SBRT and BOR for all the cases Supplementary Table S3. SBRT targets according to treatment group Supplementar…
View article: The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases
The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases Open